Pirfenidone for IPF: pro/con debate; the 'con' viewpoint.
نویسندگان
چکیده
Improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) remains a major unmet healthcare need— in this, we entirely agree with the ‘pro’ debate article by Gisli Jenkins. In this regard, the efforts of drug companies in developing novel drugs and collaboration with expert clinical investigators in the field of IPF in wanting to demonstrate the therapeutic efficacy for patients with IPF are commendable. Unfortunately, several clinical trials of novel therapy for IPF have yielded negative results. In 1999, the therapeutic potential of pirfenidone as the first antifibrotic pharmacologic agent with promises/hopes that it would improve outcomes for IPF patients was demonstrated in a phase II study. Some 13 years later, initial enthusiasm is being questioned—hence, the rationale for this pro/ con debate. In this article, it is our aim to provide a balance to Dr Gisli Jenkins’s pro article, and we hope to provide the readers of this debate a balanced view of the topic. Undoubtedly, the reader will realise that the truth probably exists between the two ends of this polarised academic debate. We believe that the clinician must assess the benefits and risks of pirfenidone treatment by addressing the following specific issues.
منابع مشابه
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
Idiopathic pulmonary fibrosis (IPF) is an incurable condition that is characterized by progressive pulmonary fibrosis, architectural distortion of the lung and loss of gas exchange units. Until recently, there was no effective treatment for this condition. However, there were two landmark trials published earlier this year, which have changed the management of this condition. Pirfenidone (Asses...
متن کاملRelaunching the Pro–Con section at Critical Care
At a recent Editorial Board meeting of Critical Care that was held in conjunction with the International Symposium of Intensive Care and Emergency Medicine in Brussels, there was a fairly lively discussion about the Pro–Con section of the journal. Despite data demonstrating that the diverse and provocative Pro–Con debates published over the years have been popular, there was a sense they could ...
متن کاملLong-term management of IPF with pirfenidone - a clinical case study with 5 years follow-up.
Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic interstitial lung disease that is associated with a median survival of 2-5 years from initial diagnosis. To date, the search for an effective treatment has involved numerous clinical trials of investigational agents but without significant success. Nevertheless, research over the past 10 years has provided us with a wealth of infor...
متن کاملThe role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive disease, with a median survival time of 2-5 years. The search for effective treatment has involved numerous clinical trials of investigational agents without significant success. However, in 2011, pirfenidone was the first drug to be approved for the treatment of IPF in Europe. Four key clinical trials supported the efficacy and tolerability ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Thorax
دوره 68 7 شماره
صفحات -
تاریخ انتشار 2013